Biotech | May 29, 2022
USFDA approves two Opdivo-based regimens
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Perrigo expects to launch Omeprazole Minis later this year
Manamed, a pioneering Medical Technology development company, has been granted FDA approval on its latest orthopaedic recovery device, ManaSport.
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
The integration and transition of the brands are expected to be completed by June 2022.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Subscribe To Our Newsletter & Stay Updated
